GlassScriptPhysician profile
Michelle Szerling
NPI 1629684048
$544.40
in general payments reported to CMS, 2019-2025
14 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $26.59 · 2023: $19.39 · 2024: $150 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $142.62 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $101.28 | 2024-2025 | Uptravi |
| W. L. Gore & Associates, INC. | $47.53 | 2021-2023 | Gore Cardioform Septal Occluder |
| Atricure, INC. | $43.01 | 2024 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $39.26 | 2025 | |
| United Therapeutics Corporation | $37.35 | 2024-2025 | Tyvaso, Tyvaso |
| Medtronic, INC. | $24.70 | 2024 | Signia |
| Lilly USA, LLC | $18.50 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $16.48 | 2024 | Keytruda |
| Verona Pharma, INC. | $16.45 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $15.58 | 2025 | Nucala |
| Integra Lifesciences Corporation | $15.29 | 2025 | Integra, Omnigraft, Surgimend |
| Bayer Healthcare Pharmaceuticals INC. | $13.40 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Szerling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.